AR076948A1 - Anticuerpos contra ccn1 (proteina rica en cisteina 61-cyr-61) humano y usos de los mismos - Google Patents
Anticuerpos contra ccn1 (proteina rica en cisteina 61-cyr-61) humano y usos de los mismosInfo
- Publication number
- AR076948A1 AR076948A1 ARP100101940A ARP100101940A AR076948A1 AR 076948 A1 AR076948 A1 AR 076948A1 AR P100101940 A ARP100101940 A AR P100101940A AR P100101940 A ARP100101940 A AR P100101940A AR 076948 A1 AR076948 A1 AR 076948A1
- Authority
- AR
- Argentina
- Prior art keywords
- ccn1
- protein
- domain
- human
- cisteine
- Prior art date
Links
- 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 title abstract 7
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 title abstract 7
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000012528 membrane Substances 0.000 abstract 3
- 101000777577 Homo sapiens CCN family member 1 Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 102000049732 human CCN1 Human genes 0.000 abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Método para la expresion recombinante de la proteína CCN1 humana, o de un dominio de la misma, unida a una membrana de una célula de mamífero, caracterizado porque se transforma una célula huésped de mamífero con un vector codificante de la proteína CCN1, o de un dominio de la misma, fusionada C-terminalmente con un dominio transmembranal de una célula de mamífero (proteína de fusion de CCN1), que expresa dicha proteína CCN1 o proteína de fusion de dominio de CCN1 en dicha célula huésped, y se recupera dicha proteína CCN1 unida a membrana, o dicho dominio de la misma. Utilizacion de dicha proteína CCN1 y dicho dominio unidos a membrana, para la generacion de anticuerpos. Un anticuerpo contra la proteína CCN1 humana resulta util para el tratamiento de enfermedades tumorales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09007389 | 2009-06-04 | ||
| EP09164765 | 2009-07-07 | ||
| EP09165886 | 2009-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076948A1 true AR076948A1 (es) | 2011-07-20 |
Family
ID=42735668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101940A AR076948A1 (es) | 2009-06-04 | 2010-06-02 | Anticuerpos contra ccn1 (proteina rica en cisteina 61-cyr-61) humano y usos de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8207307B2 (es) |
| EP (1) | EP2438084A2 (es) |
| JP (1) | JP2012528812A (es) |
| KR (1) | KR20120014941A (es) |
| CN (1) | CN102414219A (es) |
| AR (1) | AR076948A1 (es) |
| AU (1) | AU2010256000A1 (es) |
| BR (1) | BRPI1009003A2 (es) |
| CA (1) | CA2762375A1 (es) |
| IL (1) | IL216440A0 (es) |
| MX (1) | MX2011012555A (es) |
| SG (1) | SG176666A1 (es) |
| TW (1) | TW201102086A (es) |
| WO (1) | WO2010139469A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111068040B (zh) * | 2014-02-08 | 2023-03-07 | 德赛诊断系统(上海)有限公司 | Cyr61/CCN1蛋白抗原表位多肽的抑制剂SC-4-SC-15的应用 |
| EP3364190A1 (en) * | 2017-02-20 | 2018-08-22 | Panka Cancer Research AG | Method of detecting cancer or cancer cells |
| KR102721254B1 (ko) * | 2017-02-28 | 2024-10-23 | 주식회사 파이안바이오테크놀로지 | 형질전환시킨 중국햄스터난소 세포를 활용하여 시시엔5 단백질을 제조하는 방법 |
| EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| CN116715761B (zh) * | 2023-07-31 | 2024-01-26 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种治疗性单克隆抗体及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0804562B1 (en) | 1994-07-12 | 2002-10-09 | Human Genome Sciences, Inc. | Connective tissue growth factor-2 |
| US6413735B1 (en) * | 1996-03-15 | 2002-07-02 | Munin Corporation | Method of screening for a modulator of angiogenesis |
| US7521540B2 (en) | 1996-03-15 | 2009-04-21 | Munin Corporation | CYR61 compositions and methods |
| DE60128066T2 (de) * | 2000-01-31 | 2007-12-27 | Munin Corporation, Chicago | Humanes cyr61 |
| WO2001098359A2 (en) * | 2000-06-21 | 2001-12-27 | Wyeth | Cyr61 as a target for treatment and diagnosis of breast cancer |
| WO2002004480A2 (en) | 2000-07-11 | 2002-01-17 | Human Genome Sciences, Inc. | Connective tissue growth factor-2 |
| JP2004509909A (ja) | 2000-09-29 | 2004-04-02 | ワイス | ヒトの子宮平滑筋腫の治療および診断におけるｃｙｒ６１の使用 |
| TWI356097B (en) | 2003-06-20 | 2012-01-11 | Munin Corp | Ccn1 compositions and methods |
| CA2625619A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
-
2010
- 2010-06-01 TW TW099117631A patent/TW201102086A/zh unknown
- 2010-06-02 BR BRPI1009003A patent/BRPI1009003A2/pt not_active Application Discontinuation
- 2010-06-02 WO PCT/EP2010/003355 patent/WO2010139469A2/en not_active Ceased
- 2010-06-02 KR KR1020127000109A patent/KR20120014941A/ko not_active Ceased
- 2010-06-02 AR ARP100101940A patent/AR076948A1/es not_active Application Discontinuation
- 2010-06-02 JP JP2012513508A patent/JP2012528812A/ja active Pending
- 2010-06-02 SG SG2011089687A patent/SG176666A1/en unknown
- 2010-06-02 AU AU2010256000A patent/AU2010256000A1/en not_active Abandoned
- 2010-06-02 EP EP10736604A patent/EP2438084A2/en not_active Withdrawn
- 2010-06-02 CN CN2010800194420A patent/CN102414219A/zh active Pending
- 2010-06-02 CA CA2762375A patent/CA2762375A1/en not_active Abandoned
- 2010-06-02 MX MX2011012555A patent/MX2011012555A/es not_active Application Discontinuation
- 2010-06-03 US US12/793,147 patent/US8207307B2/en not_active Expired - Fee Related
-
2011
- 2011-11-17 IL IL216440A patent/IL216440A0/en unknown
-
2012
- 2012-04-13 US US13/445,983 patent/US20120258112A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL216440A0 (en) | 2012-02-29 |
| US20120258112A1 (en) | 2012-10-11 |
| BRPI1009003A2 (pt) | 2016-03-08 |
| JP2012528812A (ja) | 2012-11-15 |
| TW201102086A (en) | 2011-01-16 |
| KR20120014941A (ko) | 2012-02-20 |
| EP2438084A2 (en) | 2012-04-11 |
| WO2010139469A3 (en) | 2011-03-31 |
| CA2762375A1 (en) | 2010-12-09 |
| WO2010139469A2 (en) | 2010-12-09 |
| AU2010256000A1 (en) | 2011-11-17 |
| US8207307B2 (en) | 2012-06-26 |
| SG176666A1 (en) | 2012-01-30 |
| CN102414219A (zh) | 2012-04-11 |
| MX2011012555A (es) | 2011-12-14 |
| US20100310567A1 (en) | 2010-12-09 |
| WO2010139469A8 (en) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002761A1 (es) | Proteínas de fusión | |
| MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
| MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
| EA201290961A1 (ru) | Способы применения растворимого cd24 для лечения ревматоидного артрита | |
| CL2011001994A1 (es) | Anticuerpo antagonista que se une a la proteína ox40 humana; secuencia de adn que lo codifica; vector de clonación o de expresión que comprende dicho adn codificante; célula huésped que comprende dicho vector de clonación o expresión; proceso de producción de dicho anticuerpo; composición farmacéutica que comprende a dicho anticuerpo; uso médico de dicho anticuerpo; proteína de fusión que comprende a dicho anticuerpo. | |
| CL2011002129A1 (es) | Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17. | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| MX2016003530A (es) | Proteina de fusion. | |
| MX390943B (es) | Receptores de antígeno quimérico cd33 y usos de los mismos. | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| MX2015010836A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado. | |
| GT200900229A (es) | Coagonistas de receptor de glucagón/glp-1 | |
| EP4219721A3 (en) | Compositions and methods for selective protein expression | |
| PE20151613A1 (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
| MX386422B (es) | Moléculas efectoras químericas etiquetadas y receptores de las mismas. | |
| AR076948A1 (es) | Anticuerpos contra ccn1 (proteina rica en cisteina 61-cyr-61) humano y usos de los mismos | |
| AR073088A1 (es) | Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos | |
| CL2012001258A1 (es) | Un polipeptido de factor de von willebrand (fvw) aislado que comprende un dominio de union a factor viii (fviii), donde dicho polipeptido carece de algunos dominios del fvw, comprende una secuencia de aminoacidos de fc de inmunoglobulina; composicion y complejo proteico que lo comprende; celula que expresa dicho polipeptido; celula que expresa dicho complejo proteico; composición que comprende el complejo proteico. | |
| BR112012009854A2 (pt) | proteína de ligação de antígeno il-23 humana | |
| MX2016006709A (es) | Moduladores de aplnr y usos de estos. | |
| MX2022016002A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
| PE20120570A1 (es) | Diferenciacion de celulas madre mesenquimales | |
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| RU2013134126A (ru) | Способ снижения уровня с-концевого телопептида коллагена 2 типа | |
| BR112018012826A2 (pt) | método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |